A study of more than 800 type 2 diabetes patients revealed those who used dapagliflozin as an add-on to insulin and other diabetes medicines lost more weight and reduced insulin use compared with those who took a placebo. The findings appear in the Annals of Internal Medicine.

Related Summaries